Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.

Details

Serval ID
serval:BIB_011979DE2022
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
Journal
Journal of virology
Author(s)
Asbach B., Kibler K.V., Köstler J., Perdiguero B., Yates N.L., Stanfield-Oakley S., Tomaras G.D., Kao S.F., Foulds K.E., Roederer M., Seaman M.S., Montefiori D.C., Parks R., Ferrari G., Forthal D.N., Phogat S., Tartaglia J., Barnett S.W., Self S.G., Gottardo R., Cristillo A.D., Weiss D.E., Galmin L., Ding S., Heeney J.L., Esteban M., Jacobs B.L., Pantaleo G., Wagner R.
ISSN
1098-5514 (Electronic)
ISSN-L
0022-538X
Publication state
Published
Issued date
01/02/2019
Peer-reviewed
Oui
Volume
93
Number
3
Language
english
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Abstract
The use of heterologous immunization regimens and improved vector systems has led to increases in immunogenicity of HIV-1 vaccine candidates in nonhuman primates. In order to resolve interrelations between different delivery modalities, three different poxvirus boost regimens were compared. Three groups of rhesus macaques were each primed with the same DNA vaccine encoding Gag, Pol, Nef, and gp140. The groups were then boosted with either the vaccinia virus strain NYVAC or a variant with improved replication competence in human cells, termed NYVAC-KC. The latter was administered either by scarification or intramuscularly. Finally, macaques were boosted with adjuvanted gp120 protein to enhance humoral responses. The regimen elicited very potent CD4 <sup>+</sup> and CD8 <sup>+</sup> T cell responses in a well-balanced manner, peaking 2 weeks after the boost. T cells were broadly reactive and polyfunctional. All animals exhibited antigen-specific humoral responses already after the poxvirus boost, which further increased following protein administration. Polyclonal reactivity of IgG antibodies was highest against HIV-1 clade C Env proteins, with considerable cross-reactivity to other clades. Substantial effector functional activities (antibody-dependent cell-mediated cytotoxicity and antibody-dependent cell-mediated virus inhibition) were observed in serum obtained after the last protein boost. Notably, major differences between the groups were absent, indicating that the potent priming induced by the DNA vaccine initially framed the immune responses in such a way that the subsequent boosts with NYVAC and protein led only to an increase in the response magnitudes without skewing the quality. This study highlights the importance of selecting the best combination of vector systems in heterologous prime-boost vaccination regimens.IMPORTANCE The evaluation of HIV vaccine efficacy trials indicates that protection would most likely correlate with a polyfunctional immune response involving several effector functions from all arms of the immune system. Heterologous prime-boost regimens have been shown to elicit vigorous T cell and antibody responses in nonhuman primates that, however, qualitatively and quantitatively differ depending on the respective vector systems used. The present study evaluated a DNA prime and poxvirus and protein boost regimen and compared how two poxvirus vectors with various degrees of replication capacity and two different delivery modalities-conventional intramuscular delivery and percutaneous delivery by scarification-impact several immune effectors. It was found that despite the different poxvirus boosts, the overall immune responses in the three groups were similar, suggesting the potent DNA priming as the major determining factor of immune responses. These findings emphasize the importance of selecting optimal priming agents in heterologous prime-boost vaccination settings.
Keywords
Animals, Antibodies, Neutralizing/blood, HIV Antibodies/blood, HIV Antigens/immunology, HIV Infections/immunology, HIV Infections/prevention & control, HIV Infections/virology, HIV-1/immunology, Humans, Macaca mulatta, Male, Poxviridae, T-Lymphocytes/immunology, Vaccination, Vaccines, DNA/administration & dosage, Vaccines, DNA/immunology, Vaccinia virus/immunology, Viral Vaccines/immunology, Virus Replication, DNA vaccine, Gag-Pol-Nef, NYVAC, NYVAC-KC, T cell responses, antibody responses, gp140, human immunodeficiency virus, nonhuman primates, vaccine
Pubmed
Web of science
Open Access
Yes
Create date
19/11/2018 14:18
Last modification date
16/11/2019 7:16
Usage data